·   Log in

Archive for March 31st, 2010

Dr Reddy’s issues six bonus debentures for every one share

Wednesday, March 31, 2010 21:16

Dr Reddy's Laboratories Ltd, India's second largest drugmaker by sales, would issue bonus debentures worth 5.20 billion rupees ($116 million) to its shareholders, the company announced.

This was posted under category: Featured, Industry  |  Read Full Story  |  0 Comments
Tagged with:

Davunetide increases cognitive functions in schizophrenia: Allon

Wednesday, March 31, 2010 20:49

Davunetide significantly increases neuroprotective biomarker level in schizophrenia patients, Allon Therapeutics Inc studies showed.

This was posted under category: Discoveries  |  Read Full Story  |  0 Comments
Tagged with: ,

Oral pill to treat advanced gastric cancer tesetaxel by Genta is around the corner

Wednesday, March 31, 2010 20:32

Tesetaxel, an oral therapy against advanced gastric cancer, will soon undergo safety studies in humans.

This was posted under category: Biotech  |  Read Full Story  |  0 Comments
Tagged with: , ,

Acetylcysteine (Acetadote) could prevent liver failure: Cumberland

Wednesday, March 31, 2010 20:28

Acetylcysteine can be useful in treating liver failure, results from studies conducted by Cumberland Pharmaceuticals Inc suggest.

This was posted under category: Clinical Trials  |  Read Full Story  |  0 Comments

SciClone’s SCV-07 delays oral mucositis caused by cancer therapy

Wednesday, March 31, 2010 20:27

SCV-07, an experimental drug to treat oral mucositis caused by chemotherapy, has been shown to delay the occurrence of the severe form of the disease.

This was posted under category: health  |  Read Full Story  |  0 Comments
Tagged with:

India’s Indoco in supply pact with Aspen on generic ophthalmic drugs for emerging markets

Wednesday, March 31, 2010 8:04

Indian generic firm Indoco Remedies has entered into a supply arrangement with South Africa's Aspen on ophthalmic products for emerging markets.

This was posted under category: Industry  |  Read Full Story  |  0 Comments